Why your DNA might be the missing link in finding the right medication dose.
In short: We treat medicine as a one-size-fits-all system, but our genomes tell a different story. Pharmacogenomics studies how your unique genetic makeup influences your response to drugs, helping doctors move beyond trial-and-error to select treatments that are safer, more effective, and tailored specifically to your body's internal chemistry.
At its core, pharmacogenomics examines how genetic variation dictates both pharmacokinetics—what your body does to a drug—and pharmacodynamics—what the drug does to your body. Many common medications are processed by liver enzymes, such as those in the cytochrome P450 superfamily. If a patient carries specific genetic variants, these enzymes may function poorly or not at all, leading to dangerous drug accumulation or, conversely, a complete lack of therapeutic effect.
The clinical stakes are highest for drugs with a narrow therapeutic index, such as chemotherapy. For instance, about one-fifth of patients treated with fluoropyrimidines experience severe adverse reactions due to impaired metabolism linked to the DPYD gene. By identifying these variants before prescribing, clinicians can adjust dosages to prevent toxicity. While testing is well-established in oncology, it is increasingly relevant across cardiology, psychiatry, and primary care.
Despite the promise of precision medicine, widespread implementation faces significant hurdles. While international bodies like the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) provide consensus guidelines, routine clinical testing remains limited. In the UK, for example, only five drug-gene pairs are tested regularly, including those for azathioprine and abacavir. Overcoming these barriers requires not just better infrastructure and IT integration, but a shift toward pre-emptive or point-of-care testing.
As genomic sequencing costs continue to fall, the field is poised to expand. Future clinical practice will likely rely on automated medication surveillance systems that integrate genetic data directly into the prescription process. By moving away from the traditional trial-and-error approach, pharmacogenomics offers a path toward a future where every prescription is informed by the patient's own biological blueprint.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Introduction to pharmacogenomics — Knowledge Hub
- Also: Pharmacogenomics
To cite this card, link to https://intellectplus.co.uk/app/technology-pharmacogenomics.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Biotechnology · More in Technology · Latest · A–Z · All topics